국가: 아일랜드
언어: 영어
출처: HPRA (Health Products Regulatory Authority)
Atorvastatin
KRKA, d.d., Novo mesto
C10AA; C10AA05
Atorvastatin
40 milligram(s)
Film-coated tablet
Product subject to prescription which may be renewed (B)
HMG CoA reductase inhibitors; atorvastatin
Marketed
2010-07-21
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT ATORVASTATIN KRKA 10 MG FILM-COATED TABLETS ATORVASTATIN KRKA 20 MG FILM-COATED TABLETS ATORVASTATIN KRKA 40 MG FILM-COATED TABLETS atorvastatin READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Atorvastatin Krka is and what it is used for 2. What you need to know before you take Atorvastatin Krka 3. How to take Atorvastatin Krka 4. Possible side effects 5. How to store Atorvastatin Krka 6. Contents of the pack and other information 1. WHAT ATORVASTATIN KRKA IS AND WHAT IT IS USED FOR Atorvastatin Krka belongs to a group of medicines known as statins, which are lipid (fat) regulating medicines. Atorvastatin Krka is used to lower lipids known as cholesterol and triglycerides in the blood when a low fat diet and life style changes on their own have failed. If you are at an increased risk of heart disease, Atorvastatin Krka can also be used to reduce such risk even if your cholesterol levels are normal. You should maintain a standard cholesterol lowering diet during treatment. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE ATORVASTATIN KRKA DO NOT TAKE ATORVASTATIN KRKA - if you are allergic to atorvastatin or any of the other ingredients of this medicine (listed in section 6) - if you have or have ever had a disease which affects the liver - if you have had any unexplained abnormal blood tests for liver function - if you are a woman able to have children and not using reliable contraception - if you are pregnant or trying to become pregnant - if you are breast- 전체 문서 읽기
Health Products Regulatory Authority 24 May 2023 CRN00DHJD Page 1 of 19 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Atorvastatin Krka 40 mg film-coated tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 40 mg atorvastatin as atorvastatin calcium. Excipient with known effect: Each 40 mg film-coated tablet contains 216.20 mg of lactose. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Film-coated tablet. White, round (diameter = 10 mm), slightly convex, bevel-edged. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Hypercholesterolaemia Atorvastatin Krka is indicated as an adjunct to diet for reduction of elevated total cholesterol (totalC), LDL-cholesterol (LDL-C), apolipoprotein B, and triglycerides in adults, adolescents and children aged 10 years or older with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to Types IIa and IIb of the Fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. Atorvastatin Krka is also indicated to reduce total-C and LDL-C in adults with homozygous familial hypercholesterolaemia as an adjunct to other lipid-lowering treatments (e.g. LDL apheresis) or if such treatments are unavailable. Prevention of cardiovascular disease Prevention of cardiovascular events in adult patients estimated to have a high risk for a first cardiovascular event (see section 5.1), as an adjunct to correction of other risk factors. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology The patient should be placed on a standard cholesterol-lowering diet before receiving Atorvastatin Krka and should continue on this diet during treatment with Atorvastatin Krka. The dose should be individualised according to baseline LDL-C levels, the goal of therapy, and patient response. The usual starting dose is 10 mg once a day. Adjustment of dose should be made at intervals of 4 weeks or more. The maximum dose is 80 전체 문서 읽기